CRSP — CRISPR Therapeutics AG

Is CRSP overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

CRISPR Therapeutics AG (CRSP) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $59.81. The rating moved from Neutral to Overbought on August 19, 2026.

See all overbought Healthcare stocks →

AI analysis

CRISPR Therapeutics AG combines a differentiated gene-editing platform with multiple clinical-stage programs and strategic partnerships that provide scientific validation and funding optionality. The company's technology position and sector M&A/commercial tailwinds create meaningful upside if upcoming clinical readouts and regulatory interactions progress favorably. However, the path to commercialization remains binary: clinical, regulatory, manufacturing, and reimbursement hurdles are substantial and could produce outsized downside if outcomes are negative. Market sentiment in the near term is muted and focused on data cadence and broader biotech risk appetite; financing flexibility and partner support will be important to de-risk the program runway.

Key factors

  • Pipeline potency: multiple clinical-stage gene-editing programs with differentiated modalities and potential curative indications (e.g., ex vivo hematology programs).
  • Strategic partnerships: collaboration and co-development deals (notably with large pharma/biotech partners) that provide validation, shared development costs, and commercialization optionality.
  • Technology leadership: proprietary CRISPR/Cas platform and growing IP, positioning the firm to capture first-mover advantages in several therapeutic niches.
  • M&A and sector tailwinds: elevated biotech/pharma M&A multiples and ongoing strategic interest in gene-editing targets increase strategic optionality and takeover value.
  • Commercial & manufacturing optionality: growing demand for synthetic-biology tools and CDMO/CRO services supports access to external development and scale-up resources.
  • Valuation asymmetry vs. clinical upside: current market price discounts some clinical risk, leaving material upside if key data/readouts are positive.

Risks

  • Clinical trial risk: negative or delayed clinical results for lead programs would materially depress valuation and near-term prospects.
  • Regulatory uncertainty: novel gene-editing modalities face evolving regulatory scrutiny and potential additional data/monitoring requirements.
  • Competition: peers and large pharma entrants (e.g., other CRISPR companies and alternative gene-therapy approaches) could erode market share or pricing.
  • Manufacturing and scale-up challenges: complex ex vivo/in vivo manufacturing could create delays, cost overruns, or supply constraints.
  • Financing and dilution risk: further capital needs to advance programs could lead to equity issuance and dilution if partnerships/grants are insufficient.
  • Payer access and pricing pressure: reimbursement constraints and payer rationalization in the US and Europe could limit commercial uptake and pricing power.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CRSP — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.